SMARCB1 and cancer: Contrasted retrospectively against a background of primary tumors from RMC patients previously treated at Memorial Sloan Kettering Cancer Center and for which genomic characterization is available (10), Patient 1 displayed the conventional hallmarks of RMC including SCT diagnosis, right kidney as tissue of origin (approximately 2/3 cases), and loss of SMARCB1/INI1 expression as revealed by IHC (Figure 1A) (1, 2).